AHFS/Drugs.com Monograph ATC code L01DB06 (WHO) Biological half-life 22 hours CAS ID 58957-92-9 | MedlinePlus a691004 Legal status US: ℞-only Molar mass 497.494 g/mol Protein binding 97% | |
 | ||
Pregnancycategory US: D (Evidence of risk) | ||
Idarubicin /ˌaɪdəˈruːbᵻsɪn/ or 4-demethoxydaunorubicin is an anthracycline antileukemic drug. It inserts itself into DNA and prevents DNA unwinding by interfering with the enzyme topoisomerase II. It is an analog of daunorubicin, but the absence of a methoxy group increases its fat solubility and cellular uptake. Similar to other anthracyclines, it also induces histone eviction from chromatin.
It belongs to the family of drugs called antitumor antibiotics.
It is currently combined with cytosine arabinoside as a first line treatment of acute myeloid leukemia.
It is distributed under the trade names Zavedos (UK) and Idamycin (USA).
References
Idarubicin Wikipedia(Text) CC BY-SA